CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - 30/12/21
Doi : 10.1016/S1470-2045(21)00702-6
Pierpaolo Correale a, b, Francesca Pentimalli c, Valerio Nardone d 
, Antonio Giordano b, e, Luciano Mutti b, f
, Antonio Giordano b, e, Luciano Mutti b, f a Medical Oncology Unit, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy
b Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA
c Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G Pascale, Naples, Italy
d Department of Precision Oncology, University Hospital of Campania “L Vanvitelli”, Naples 80138, Italy
e Department of Medical Biotechnologies, University of Siena, Siena, Italy
f Italian Group for Research and Therapy for Mesothelioma (GIMe), Voghera, Italy
Le texte complet de cet article est disponible en PDF.
© 2022
Elsevier Ltd. Tous droits réservés.
Vol 23 - N° 1
P. e13 - janvier 2022 Retour au numéro
Article précédent
- Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer – Author’s reply
- Changhoon Yoo, NIFTY trial investigators
- CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors’ reply
- Dean A Fennell, Gareth Griffiths, Christian Ottensmeier, Gerard G Hanna, Sarah Danson, Peter Szlosarek, Mavis Nye
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?